Syndax Pharmaceuticals (SNDX) Other Operating Expenses (2022 - 2026)

Syndax Pharmaceuticals' Other Operating Expenses history runs 4 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• On a quarterly basis, Other Operating Expenses rose 197.51% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was -$10.2 million, a 127.65% decrease from a year earlier, with the FY2025 full-year figure at $1.3 million, up 419.43% from the prior year.
• Other Operating Expenses grew to $2.6 million in Q1 2026 per SNDX's latest filing, from -$2.1 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $52.1 million in Q3 2024 and bottomed at -$11.8 million in Q2 2024.
• The 4-year median for Other Operating Expenses is -$2.1 million (2025), against an average of $4.5 million.
• Across the five-year window, Other Operating Expenses tumbled 113.44% in 2025 and soared 197.51% in 2026, its largest moves.
• Year by year, Other Operating Expenses stood at $13.7 million in 2022, then slumped by 132.15% to -$4.4 million in 2024, then surged by 52.6% to -$2.1 million in 2025, then soared by 225.8% to $2.6 million in 2026.
• Per Business Quant, the three latest SNDX Other Operating Expenses figures stand at $2.6 million (Q1 2026), -$2.1 million (Q4 2025), and -$7.0 million (Q3 2025).